Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02804763
Recruitment Status : Completed
First Posted : June 17, 2016
Last Update Posted : July 9, 2019
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 31, 2018
Actual Study Completion Date : November 15, 2018
Certification/Extension First Submitted : June 19, 2019